Whilst the head-to-head data in psoriasis has established superior efficacy of dual IL-17A and IL-17F in the skin compared to other biologic disease modifying anti-rheumatic drugs (bDMARDS) such as adalimumab and secukinumab, similar efficacy was observed at the joint compared to anti-TNF. This evidence concerns the gene IL17F and psoriasis.